Bloomberg	Pharmaceuticals ALPM IN 533573				
RATING	BUY				
СМР	999				
Price Target	1140				
Potential Upside	14%				

Rating Change	1
Estimate Change	1
Target Change	1 I

STOCK INFO	
52wk Range H/L	1044/436
Mkt Capital (Rs Cr)	19019
Free float (%)	27%
Avg. Vol 1M (,000)	464
No. of Shares (Crs)	19
Promoters Pledged %	0%

#### **RESEARCH ANALYST**

#### **J MADHAVI**

j.madhavi@narnolia.com

India Equity Analytics 23-Jul-20 Result Update

## Lower promotional and R&D spends on account of Covid led to margins expansion.

#### 1QFY21 Result Update

- The US business grew by 73% YoY to Rs. 596 crs on account of lower base in the previous quarter, sequentially grew by 3% with Sartans portfolio becoming more stabilized.
- Other international business grew by 62% YoY to Rs. 175 crs on account of increased growth from Europe & RoW on the lower base of previous quarter due to serialization issues.
- The Domestic business declined by 6% YoY to Rs. 306 crs on account of strict lockdown in the month of April & May. The portfolio of products in the India business saw some drags in specific areas of Liquid formulation segment, Hormones & Gynecology.
- API grew by 53% YoY to Rs. 264 crs on account Azithromycin API & other opportunities on account of China disruption.
- The gross margin de-grew by 360 bps YoY to 74.8% this quarter on account of increased contribution from the API in the overall mix; while EBITDA margin grew by 670 bps YoY on account of reduced travelling, promotional & R&D expenses this quarter compared to 1QFY20 due to Covid.
- PAT for the quarter grew by 145% YoY to Rs.301 crs based on increased sales growth & reduced operating cost due to Covid.

#### **View and Valuation**

APLLTD has reported strong numbers this quarters backed by growth in the International markets & API segment despite an exceptionally challenging environment. We expect the overall revenues to grow at a 16% CAGR over FY20-22. The ramp up in the filings from the new dosages form i.e., Ophthalmology, General Injectables, Oncology Injectables, and Dermatology would add to the overall growth in the US sales from 2HFY22 onwards. The Ex-US business has stayed impacted for the last 2 years on account of serialization; with the serialization issues now being resolved, we expect this geography to contribute significantly in FY21 on the lower base of FY20. The India business has stayed impacted on account of lockdown in 1QFY21, though we expect revival from the next quarter. The API segment is expected to grow by 15-20% for the full year on the back of disruption in China & increased sale of Azithromycin API.

On the margin front, we expect EBITDA margin to be subdued in FY21 based on increasing contribution from relatively lower margin new launches in the US and increased API & ROW contribution in the overall mix. Therefore, we increased our rating from NEUTRAL to BUY at target price of Rs.1140 at 22x FY22E EPS.

#### Key Risks to our rating and target

Delay ANDA filings and approval from the new plants.

					Fig in Rs Cr
<b>KEY FINANCIAL/VALUATIONS</b>	FY18	FY19	FY20	FY21E	FY22E
Net Sales	3131	3935	4606	5484	6215
EBITDA	643	874	1223	1467	1672
EBIT	538	758	1066	1288	1422
PAT	413	584	829	980	1044
EPS (Rs)	22	31	44	52	55
EPS growth (%)	2%	42%	42%	18%	7%
ROE (%)	18.6%	21.5%	25.8%	25.6%	23.1%
ROCE (%)	19.8%	23.6%	26.0%	27.4%	26.3%
BV	47	85	101	118	144
Р/В (Х)	4.7	3.7	3.9	4.9	4.2
P/E (x)	25.1	17.1	15.1	19.2	18.0

The views expressed above accurately reflect the personal views of the authors about the subject companies and its(their) securities. The authors have not and will not receive any compensation for providing a specific recommendation or view. Narnolia Financial Advisors Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

#### Please refer to the Disclaimers at www.narnolia.com

1QFY21 Results										Fig in Rs Cr
FINANCIALS	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	YoY%	QoQ%	FY19	FY20	ΥοΥ%
Net Sales	949	1,241	1,209	1,207	1,341	41.4%	11.1%	3,935	4,606	17.1%
Other Income	3	0	0	0.9	0.3	-90.3%	-64.0%	9	5	-47.3%
COGS	204	273	298	264	338	65.2%	28.0%	993	1,039	4.7%
Gross Margin	78.5%	78.0%	75.3%	78.1%	74.8%	-3.6%	-3.3%	74.8%	77.4%	2.7%
Employee Cost	215	218	227	247	275	28.2%	11.5%	747	906	21.4%
Other Expen.	305	405	359	369	321	5.3%	-12.9%	1,322	1,437	8.7%
EBITDA	225	346	325	328	407	81.1%	24.4%	874	1,223	40.0%
EBITDA Mar.	23.7%	27.8%	26.9%	27.1%	30.4%	6.7%	3.2%	22.2%	26.6%	4.4%
Depreciation	35	36	42	44	42	17.2%	-6.0%	115	157	36.5%
EBIT	190	310	283	283	366	93%	29.1%	758	1,066	40.5%
Interest	5	7	7	8	7	34%	-13.9%	18	27	47.5%
PBT	188	303	276	277	360	91.4%	30.0%	749	1,043	39%
Exceptional Item	33	-	-	11	-	-	-	-	44	
Тах	36	52	49	62	67	85.7%	7.5%	157	199	27%
PAT	123	246	235	224	301	144.6%	33.9%	584	829	42%
PAT Margin	13.0%	19.8%	19.4%	18.6%	22.4%	9.5%	3.8%	14.9%	18.0%	3%

#### 1QFY21 Results

### **Concall Highlights**

- The US business grew by 73% YoY to Rs. 596 crs, sequentially grew by 3% with Sartans portfolio becoming more stabilized.
- For sartans- the company is present in 14 sartans (Constituting 40% of the 12 months sales in US)
- In the US, the Opthalmics has been doing really good; the company has picked up good market share in. In Derma, the competition is quite high & the company is gradually ramping up.
- The strategy of the company is to lighten the balance sheet & invest in complex generics & 505(b)(2) products in the US market.
- Other international business grew by 62% YoY to Rs. 175 crs on account of increased growth from Europe & RoW on the lower base of previous quarter due to serialization issues. With serialization issues now being over, the company expects the Ex-US market to grow going ahead.
- API grew by 53% YoY to Rs. 264 crs on account Azithromycin API & other opportunities on account of China disruption. The company expects API to grow at around 15-20% for the full year.
- The company filed 8 ANDAs & received 6 approvals from the USFDA this quarter. Total 3 products were launched in this quarter, with 5 launches expected in 2QFY21. For the full year, the company expects to launch 15-20 products in US in FY21.
- The Domestic business declined by 6% YoY to Rs. 306 crs on account of strict lockdown in the month of April, May & parts of June. The portfolio of products in the India business saw some drags in specific areas of Liquid formulation segment, Hormones & Gynecology.
- Going ahead in the India business, the company expects to see improvement with good pickup in the monsoon, benefits
  flowing in through the changed strategy & strong uptick in the Azithromycin oral solids though Azithromycin liquids will see
  substantial drag.
- Other expenses has declined 5% YoY & 14% sequentially on account of lower travelling & promotional expenses, along with that the R&D spends were on the lower side impacted by Covid.
- Plant details:
- F2 OSD & Injectables plant (Oncology) OSD block has been audited twice; for the Injectable plant, batches are ongoing with filings expected in the next 6 months.
- F3- General Injectables plant- Filed 3-4 products.
- F4- Jarod OSD plant- Expects to file batches in the next 6 months.
- The company expects to spend 700 crs in the next 1-2 yrs for expansion in the injectables & Jarod plant. The company also have some investment plans for the API segment.
- $\circ~$  The gross debt for the company stands at Rs. 1439 crs, cash in hand at 260 crs.


### Exhibit: Sales and Sales Growth

Sales for the quarter grew by 41% YoY to Rs.1341 crs based on higher than expected sales in API & Row markets.



### Exhibit: Cumulative ANDA filings and approvals

The company filed 8 ANDA and received 6 ANDA approvals in 1QFY21.




### Exhibit: US sales and YoY growth

The US business grew strongly by 67% to US% 79 mn on account of lower base in the previous year.




### Exhibit: Grorss and EBITDA margin

GM declined due to higher API sales while EBITDA margin grew on lower promotional & R&D spends.



#### Exhibit: R&D cost and R&D as a % of sales

R&D spends declined in Q1FY21 to Rs143 crs (11% of sales) vs 140 crs (15% of sales) in 1QFY20.



### Exhibit: Domestic sales and YoY growth

Domestic sales for the quarter declined by 6% YOY to Rs.306 crs on account of lockdown.



#### Growth to be seen across geographies going ahead

In the US market, the company grew by 51% in FY20 on account of Sartans opportunity & launch of Febuxostat with 180 days of exclusivity. Going forward, we estimate a growth of 14% in FY21 on the higher base of FY20 with 15-20 expected launches. The further ramp up in the ANDA filings from the new facilities would add to the overall growth in the US sales from 2HFY22 onwards.

The Domestic formulation business stayed impacted in 1QFY21 due to strict lockdown in the months of April & May. The Liquid formulation segment, Hormones & Gynecology saw some drag due to change in customer's behaviour with increased number of Covid cases. Going ahead, we expect India business to improve on account of good pickup in monsoon, benefits flowing in through the changed strategy & strong uptick in the Azithromycin oral solids.

For the last 5 quarters, Serialization in Europe has been impacting the ROW sales of the company. With the serialization issue now being resolved, we expect Ex-US to grow by 41% in FY21 on the lower base of Fy20.

The API sales this quarter grew by 53% YoY to Rs. 264 crs on account of increased sales of Azithromycin API & other opportunities due to disruption in China. The API sales has been lumpy for Alembic over the last 4 years as it was engaged in contract manufacturing; excluding the CRAMS business, the API segment has grown at 15% CAGR as per the company. Going forward, the company plans to expand its API capacity to grab the opportunities coming in as the country moves to reduce its dependency on China.

## **Operational Details**

									Fig in Rs Cr
GEOGRAPHY	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21
India Formulation	331	385	365	302	324	391	368	342	306
US	225	417	308	313	345	539	515	577	596
ROW	127	170	140	82	108	107	149	132	175
API	179	155	205	230	172	204	177	155	264

<b>REVENUE GR. %</b>	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21
India Formulation	40%	0%	5%	-1%	-2%	2%	1%	13%	-6%
US	7%	118%	30%	8%	53%	29%	67%	84%	73%
ROW	80%	141%	88%	29%	-15%	-37%	6%	61%	62%
API	38%	9%	14%	16%	-4%	32%	-14%	-33%	53%

<b>REVENUE MIX %</b>	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21
India Formulation	38%	34%	36%	33%	34%	32%	30%	28%	23%
US	26%	37%	30%	34%	36%	43%	43%	48%	44%
ROW	15%	15%	14%	9%	11%	9%	12%	11%	13%
API	21%	14%	20%	25%	18%	16%	15%	13%	20%

R&D spend	122	145	112	120	140	174	146	185	143
ANDA filings	3	8	4	14	4	5	6	10	8
ANDA approvals	3	0	7	6	9	6	8	11	6

## **Financial Details**

### **Balance Sheet**

Salarice Sheet						-		Fig in Rs Cr
Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Share Capital	38	38	38	38	38	38	38	38
Reserves	847	1,560	1,865	2,182	2,681	3,182	3,783	4,476
Networth	885	1,597	1,902	2,220	2,719	3,220	3,821	4,514
Debt	238	114	89	708	928	1,718	1,718	1,718
Other Non Current Liab	54	84	94	97	71	160	160	160
Total Capital Employed	866	1,560	1,865	2,682	3,180	4,069	4,670	5,363
Net Fixed Assets (incl CWIP)	595	801	1,196	2,000	2,706	3,397	3,635	3,877
Non Current Investments	2	0	0	0	49	18	18	18
Other Non Current Assets	-	30	71	71	62	111	132	149
Non Current Assets	750	917	1,317	2,116	2,820	3,557	3,817	4,076
Inventory	383	570	633	734	967	1,188	1,352	1,532
Debtors	361	350	339	526	489	865	1,037	1,175
Cash & Bank	27	439	153	84	199	72	123	316
Other Current Assets	-	127	227	441	287	290	345	391
Current Assets	891	1,511	1,372	1,825	1,958	2,432	2,867	3,426
Creditors	325	566	501	759	702	626	676	766
Provisions	95	7	12	14	32	38	38	38
Other Current Liabilities	45	61	91	143	326	227	270	306
Curr Liabilities	464	633	604	916	1,061	891	985	1,111
Net Current Assets	426	878	768	909	897	1,541	1,883	2,316
Total Assets	1,641	2,429	2,689	3,941	4,778	5,989	6,684	7,503

### **Income Statement**

income Statement								Fig in Rs Cr
Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Revenue from Operation	2,056	3,166	3,135	3,131	3,935	4,606	5,484	6,215
Change (%)	10%	54%	-1%	0%	26%	17%	19%	13%
EBITDA	403	1007	615	643	874	1223	1467	1672
Change (%)	13%	150%	-39%	5%	36%	40%	20%	14%
Margin (%)	20%	32%	20%	21%	22%	27%	27%	27%
Depr & Amor.	44	72	83	105	115	157	178	251
EBIT	359	934	532	538	758	1066	1288	<b>1</b> 422
Int. & other fin. Cost	2	5	5	3	18	27	34	69
Other Income	2	7	2	7	9	5	5	8
EBT	359	936	529	541	749	1043	1259	1360
Exp Item	-	-	-	-	-	44	-	-
Тах	76	216	122	120	157	199	269	306
Minority Int & P/L share of Ass.	0	(0)	(4)	(8)	(8)	28	(10)	(10)
Reported PAT	283	720	403	413	584	829	980	1,044
Adjusted PAT	283	720	403	413	584	873	980	1,044
Change (%)	20%	155%	-44%	2%	42%	49%	18%	7%
Margin(%)	14%	23%	13%	13%	15%	18%	18%	17%

Eig in Do Cr

## **Financial Details**

## **Key Ratios**

Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
ROE	32.0%	45.1%	21.2%	18.6%	21.5%	25.8%	25.6%	23.1%
ROCE	39.7%	58.5%	28.0%	19.8%	23.6%	26.0%	27.4%	26.3%
Asset Turnover	1.3	1.3	1.2	0.8	0.8	0.8	0.8	0.8
Debtor Days	71	62	39	61	45	69	69	69
Inv Days	68	66	74	86	90	94	90	90
Payable Days	58	65	58	89	65	50	45	45
Int Coverage	201	172	102	158	41	39	37	21
P/E	30.2	15.7	29.2	25.1	17.1	15.1	19.2	18.0
Price / Book Value	9.7	7.1	6.2	4.7	3.7	3.9	4.9	4.2
EV/EBITDA	21	11	19	17	12	11	13	12
FCF per Share	(3)	34	(10)	(23)	8	(12)	23	33
Div Yield	1%	1%	1%	1%	1%	2%	2%	2%

## **Cash Flow Statement**

								Fig in Rs Cr
Y/E March	FY15	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
РВТ	359	936	529	541	749	1,000	1,249	1,350
(inc)/Dec in Working Capital	(163)	139	(166)	(181)	109	(584)	(321)	(257)
Non Cash Op Exp	44	72	83	105	115	157	178	251
Int Paid (+)	4	5	5	3	18	27	34	69
Tax Paid	(69)	(197)	(118)	(135)	(166)	(236)	(269)	(306)
others	(4)	(8)	(5)	(22)	(13)	85	(27)	-
CF from Op. Activities	172	948	329	312	812	449	845	1,106
(inc)/Dec in FA & CWIP	(224)	(301)	(510)	(749)	(654)	(673)	(416)	(493)
Free Cashflow	(52)	647	(182)	(437)	158	(223)	428	613
(Pur)/Sale of Inv	(34)	(8)	4	-	-	-	-	-
others	2	2	1	(149)	(106)	(60)	-	-
CF from Inv. Activities	(256)	(307)	(486)	(884)	(756)	(732)	(416)	(493)
inc/(dec) in NW						-	-	-
inc/(dec) in Debt	157	(132)	(39)	619	221	609	-	-
Int. Paid	(5)	(5)	(5)	(26)	(70)	(111)	(34)	(69)
Div Paid (inc tax)	(65)	(79)	(90)	(91)	(91)	(326)	(352)	(352)
others	0	(8)	5	0	(0)	(18)	-	-
CF from Fin. Activities	87	(224)	(129)	503	59	155	(386)	(420)
Inc(Dec) in Cash	3	417	(286)	(69)	115	(128)	42	193
Add: Opening Balance	24	23	439	153	84	199	81	123
Closing Balance	27	439	153	84	199	72	123	316

Narnolia Financial Advisors Ltd. is a SEBI registered Research Analyst having SEBI Registration No. INH300006500. The Company/Analyst (s) does/do not have any holding in the stocks discussed but these stocks may have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.

The stocks recommended are based on our analysis which is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed.

Disclosures: Narnolia Financial Advisors Ltd. (NFAL) (FormerlyMicrosec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300006500. NFALis engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority. NFAL, it's associates, Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. NFAL and/or its associates may have received compensation for the report. NFAL or any of its associates may have: a) managed or co-managed public officing of securities from subject company of this research report. NFAL and it's associates have not erechant banking or merchant banking or brokerage services from the subject compensation of received compensation for investment banking or anerchant banking or merchant banking or brokerage services from the Subject company of this research report. NFAL and it's associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and it's associates hav

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement-

Applyst's ownership of the steelys mentioned in the Depart	NIII
Analyst's ownership of the stocks mentioned in the Report	NIL

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.

Registered Office Address: Marble Arch, Office 201, 2nd Floor, 236B, AJC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300006500, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 || Narnolia Commerze Limited (Formerly Microsec Commerze Ltd.)-MCX/NCDEX Commodities Broker: INZ000051636 || NarnoliaVelox Advisory Ltd.- SEBI Registered PMS: INPO0005109 || Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SEBI Registered Investment Adviser: INA300005439 || Narnolia Insurance Brokers Limited (Formerly Microsec Insurance Brokers Ltd.)-IRDA Licensed Direct Insurance Broker (Life & Non-Life) Certificate No. 134, License No. DB046/02 || Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered NBFC:B.05.02568.

#### Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL) and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the customers simultaneously, not all custome

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.